Archive

Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report

Painful symmetrical hyperkeratotic plantar plaques appeared approximately eight weeks after starting sorafenib, impairing daily activities; managed with topical keratolytic and corticosteroid therapy.

Oncology · Cureus · 25 Sept

Unraveling the lexicon of complex mutational phenomena in human cancers.

No new data; the review clarifies ambiguous definitions and proposed origins of these eight phenomena and notes their reported associations with mutational processes, drug resistance and clinical outcomes

Oncology · Nature cancer · 25 Sept

Antimicrobial Resistance of Bacteria Isolated From Patients With Cancer

Enterobacteriaceae were 73.1% of isolates; ESBL prevalence 22.6%. E. coli MDR 51.0%, K. pneumoniae XDR 32.2%, Acinetobacter possible PDR 14.3%. E. coli resistance rose for ciprofloxacin and ceftriaxone in 2021.

Oncology · Cureus · 25 Sept

Cigna Group, OpenAI team up to support patients with complex conditions

Insurer-led AI navigation for cancer patients may change who coordinates your patients' care between visits, and what they bring to clinic.

Oncology · Fierce Healthcare · 24 Sept

Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy

Endomyocardial biopsy confirmed focal moderate lymphocytic myocarditis; troponin I, creatine phosphokinase, lactate dehydrogenase and transaminases were markedly elevated; acetylcholine receptor binding and muscle-specific kinase antibodies were negative.

Oncology · Cureus · 24 Sept

Complete Response to First-Line Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Extra-axial Central Nervous System Metastases

Suggests T-DXd can be used first-line for HER2-positive extra-axial CNS metastases, where treatment options are limited and prognosis poor.

Oncology · Cureus · 24 Sept

Grail survives adcomm vote as it awaits FDA decision for cancer blood test

A positive FDA panel vote moves Galleri closer to approval as a multi-cancer screening blood test, though its earlier trial miss means sensitivity limits still matter for how you counsel patients.

Oncology · Fierce Biotech · 24 Sept

Optimizing the delivery of radiotherapy with artificial intelligence.

AI already automates contouring, planning and QA in radiotherapy; knowing where it is validated tells you which tasks you can safely delegate.

Oncology · Nature reviews. Clinical oncology · 24 Sept

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.

Adds a CD47-blocker to standard second-line HER2 therapy in pretreated gastric cancer; check the response data before considering it for your patients.

Oncology · Nature Medicine · 24 Sept

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

Of 38 treated, all 38 (100%) responded and 79% had complete response. At median follow-up 38.1 months, 24-month PFS was 57%, median PFS 30.2 months, 36-month OS 65%.

Oncology · NEJM · 24 Sept

Oracle Health rolls out AI solutions for RCM, oncology as part of broader healthcare, life sciences strategy

If your hospital runs Oracle Cerner, expect AI-driven coding and oncology workflow tools to reach your EHR; ask how they handle clinical validation and billing accuracy.

Oncology · Fierce Healthcare · 24 Sept

Barriers to Biomarker-Guided Advanced Breast Cancer Care in India: Diagnostic, Economic, and Implementation Challenges

Before prescribing HER2 or HR-directed therapy, check that your patient can actually access and afford the biomarker test — that gap, not drug choice, drives outcomes here.

Oncology · Cureus · 23 Sept

Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.

If your myeloma patient on cilta-cel develops severe diarrhoea, mucosal CAR-T persistence and inflammatory remodelling suggest this is a distinct, durable enterocolitis needing its own management.

Oncology · Nature Medicine · 23 Sept

Utility of Artificial Intelligence in Detecting Lymph Node Metastasis in Oral Cancer: A Systematic Review

AI models may flag occult nodal disease that conventional imaging misses in OSCC, potentially sparing some patients unnecessary neck dissection while catching others earlier.

Oncology · Cureus · 22 Sept

Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy

SBRT can control intramedullary cord metastases without surgery, so consider radiotherapy referral for oligometastatic melanoma patients with cord lesions and progressive myelopathy.

Oncology · Cureus · 22 Sept

Stereotactic Radiosurgery for an Unresectable Jugulotympanic Paraganglioma: Clinical Response and Acute Toxicity in a 70-Year-Old Patient

In elderly patients with unresectable skull-base paraganglioma, radiosurgery can control a slow-growing tumour while sparing nearby cranial nerves.

Oncology · Cureus · 22 Sept

Blood test may help detect pancreatic cancer in earliest stages: Researchers

A sensitive stage 1-2 pancreatic cancer blood test could finally enable screening in high-risk patients, where CA19-9 and imaging currently miss early disease.

Oncology · ETHealthworld · 22 Sept

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial.

Adds HER2 blockade to first-line chemoimmunotherapy for HER2-positive biliary tract cancer; check HER2 status at diagnosis since this subset now has a targeted option.

Oncology · Nature Medicine · 22 Sept

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.

Blood-based multicancer screening added to usual care did not reduce late-stage cancer diagnoses, so it should not be offered as a routine screen yet.

Oncology · NEJM · 22 Sept

Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.

Cancer detection rate 0.54% (95% CI 0.47-0.63%); PPV 60.3%; NPV 99.2%; specificity 99.64%; episode sensitivity 39.3% all cancers, 69.8% in prespecified 12-cancer subgroup; number needed to screen 185.

Oncology · Nature Medicine · 22 Sept

Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.

Primary endpoint of reduced stage III/IV cancer incidence was not met. Positive predictive value fell from 58.0% to 45.8% across rounds; episode sensitivity 26.7-37.2% for all cancers, 47.6-63.4% for 12 prespecified types.

Oncology · Nature Medicine · 22 Sept

An iron-regulated methionine redox axis governs adipose browning and cancer cachexia.

MsrA deletion impaired adipose browning, mitigated cachexia and prolonged survival of tumour-bearing mice. Iron-bound MSRA dimers promote browning by maintaining reduced protein kinase A catalytic subunit.

Oncology · Nature cancer · 22 Sept

Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence.

In external testing (8 centres, n=11,466), specificity was 98.5%, sensitivity 90.0% for cancer and 52.5% for precancerous lesions. Real-world low-dose screening (n=10,959) reached 99.94% specificity.

Oncology · Nature Medicine · 22 Sept

Aetna expands bundled prior auths for cancer care

If your Medicaid cancer patients are Aetna-insured, one bundled auth now covers a whole regimen instead of separate approvals per drug and scan.

Oncology · Fierce Healthcare · 21 Sept

Esophageal Carcinoma Incidence and Survival Analysis: A Population-Based Cancer Registry Study in Central India

Median survival 178.33 days; 1-, 3-, 5-, 10-year OS 31.3%, 19.7%, 17.4%, 14.6%. Median survival 232 days localized vs 68 days distant disease. Chemoradiotherapy HR 0.48, surgery plus chemotherapy HR 0.45.

Oncology · Cureus · 21 Sept

Prevalence of Deep Vein Thrombosis in Patients With Cervical Cancer

Baseline and on-treatment DVT screening in cervical cancer patients may catch silent thrombosis before it becomes life-threatening.

Oncology · Cureus · 21 Sept

Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Consolidation of radiopharma supply could affect availability and cost of lutetium-177 therapies you refer patients for, including neuroendocrine and prostate cancer.

Oncology · Fierce Biotech · 21 Sept

Understanding and targeting the tumour matrisome.

ECM accumulation tracks with tumour aggressiveness across cancers, so matrix-directed targets may offer a new axis beyond cytotoxic therapy.

Oncology · Nature reviews. Clinical oncology · 21 Sept

Vaccines for Cancer: A Translational Science Review.

Sipuleucel-T reduced all-cause mortality in metastatic castrate-resistant prostate cancer (32% vs 23%; HR 0.78). Talimogene laherparepvec increased 6-month response in advanced melanoma (16.3% vs 2.1%). mRNA-4157 plus pembrolizumab improved relapse-free survival (76.6% vs 60%).

Oncology · JAMA · 21 Sept

Association Between Electronic Health Record Health Maintenance Topic and Lung Cancer Screening Completion in a Resident-Run Clinic

130 of 305 (43%) completed LDCT. The LCS topic was added in 96 of 130 (74%) screened versus 86 of 175 (49%) unscreened patients; association significant at p<0.001.

Oncology · Cureus · 20 Sept

Impact of Obesity on Chemotherapy Pharmacokinetics, Toxicity, and Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia

Obesity was linked to delayed high-dose methotrexate elimination, modestly reduced pegaspargase clearance, lower thioguanine nucleotide concentrations, more hepatotoxicity, pancreatitis, hyperbilirubinemia and vincristine neuropathy, and inferior survival in some cohorts.

Oncology · Cureus · 20 Sept

Povidone-Iodine Versus Homemade Salt/Soda Mouthwash for the Prophylaxis of Radiation-Induced Oral Mucositis in Head and Neck Cancer: A Quasi-experimental Study

If a cheap salt-and-soda rinse matches povidone-iodine, you can spare head-and-neck radiotherapy patients the cost and iodine exposure during treatment.

Oncology · Cureus · 19 Sept

Researchers find genetic answer to lung cancer in those who never smoked

A rare inherited EGFR variant raised lung cancer risk 25-fold in never-smokers, so consider germline testing in non-smoking patients with lung cancer and their families.

Oncology · ETHealthworld · 19 Sept

Potential Use of AI Chatbots by Patients With Bowel Tumors: Opportunities and Implications for Low- and Middle-Income Countries

Patient-facing tools supported feasibility, acceptability, symptom reporting and communication; accuracy for screening, diagnosis and treatment advice varied by task and was less reliable in complex cases.

Oncology · Cureus · 19 Sept

Assessment of Preoperative Serum Vitamin D Levels in Differentiated Thyroid Cancer

If low preoperative vitamin D tracks with differentiated thyroid cancer, it is a cheap, already-ordered test that could flag patients needing closer thyroid evaluation.

Oncology · Cureus · 18 Sept

Pulsed Low-Dose-Rate Radiotherapy (PLDR): A Comprehensive Review of Radiobiological Rationale and Clinical Applications in Modern Cancer Care

PLDR lets you re-irradiate previously treated fields with less normal-tissue toxicity, useful when reirradiation is the only local option left.

Oncology · Cureus · 18 Sept

BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data

A novel degrader-antibody conjugate failed early phase 1, a reminder that promising preclinical oncology platforms often do not translate into tolerable human activity.

Oncology · Fierce Biotech · 18 Sept

Precision prevention and early detection: framework for a new clinical cancer control pathway.

Only 13% of cancers are found by screening and up to half present via emergency, so risk-stratified prevention and detection pathways could shift your patients to earlier-stage diagnosis.

Oncology · Lancet · 18 Sept

A universal visual foundation model for computational cytopathology.

CROWN achieved best overall performance among established pretrained encoders; accuracy exceeded 95% in 48 patch-level classification evaluations and 98% in 22 of them.

Oncology · Nature cancer · 18 Sept

A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?

Tumour response was unchanged with molecular hydrogen versus control: RR 0.98 (95% CI 0.83-1.15); randomised trials only, RR 0.99 (95% CI 0.84-1.17). Narrative synthesis reported reduced radiation-induced toxicities.

Oncology · Cureus · 17 Sept